Inclusion Criteria

last updated: 04/2019

Kinase-/ JAK -Inhibitoren
Jyseleca® (Filgotinib)
Olumiant® (Baricitinib)
Rinvoq® (Upadacitinib)
Xeljanz® (Tofacitinib)

Biologika
Cimzia® (Certolizumab Pegol)
Enbrel® (Etanercept)
Humira® (Adalimumab)
Kevzara® (Sarilumab )
MabThera® (Rituximab)
Orencia® (Abatacept)
Remicade® (Infliximab)
RoActemra® (Tocilizumab)
Simponi® (Golimumab)

Biosimilar
Amgevita® (Adalimumab)
Benepali® (Etanercept)
Erelzi® (Etanercept)
Flixabi® (Infliximab)
Hulio® (Adalimumab)
Hyrimoz® (Adalimumab)
Idacio® (Adalimumab)
Imraldi® (Adalimumab)
Inflectra® (Infliximab)
Nepexto® (Etanercept)
Remsima® (Infliximab)
Rixathon® (Rituximab)
Ruxience® (Rituximab)
Zessly® (Infliximab)

Kontrollgruppe
Alle zugelassenen csDMARDs